Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

Bachar Samra; Ahmad S. Alotaibi; Nicholas J. Short; Joseph D. Khoury; Farhad Ravandi; Rebecca Garris; Nitin Jain; Marina Konopleva; Hagop Kantarjian; Elias Jabbour

doi:10.1002/ajh.25896

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

Bachar Samra
, Ahmad S. Alotaibi
, Nicholas J. Short
, Joseph D. Khoury
, Farhad Ravandi
, Rebecca Garris
, Nitin Jain
, Marina Konopleva
, Hagop Kantarjian
, Elias Jabbour

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E245-E247
Journal	American Journal of Hematology
Volume	95
Issue number	9
DOIs	https://doi.org/10.1002/ajh.25896
State	Published - Sep 1 2020
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25896

Cite this

@article{1f0b39fb34154fedb01856349d7bbc76,

title = "Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma",

author = "Bachar Samra and Alotaibi, \{Ahmad S.\} and Short, \{Nicholas J.\} and Khoury, \{Joseph D.\} and Farhad Ravandi and Rebecca Garris and Nitin Jain and Marina Konopleva and Hagop Kantarjian and Elias Jabbour",

note = "Funding Information: E. Jabbour: Research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. F. Ravandi: Honoraria/member advisory boards with BMS, Novartis, AbbVie and Amgen. M. Konopleva: Consulting/honoraria from AbbVie, Genentech, F. Hoffman La‐Roche, Stemline Therapeutics, Amgen, Forty‐Seven, Kisoji; research funding/clinical trials support: AbbVie, Genentech, F. Hoffman La‐Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca, Forty‐Seven; stock options/royalties: Reata Pharmaceutical. H. Kantarjian: Grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi‐Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. N.J. Short has served as consultant for Takeda Oncology and AstraZeneca, reports receiving commercial research grants from Takeda Oncology and Astellas Pharma Inc., and has received speakers{\textquoteright} bureau honoraria from Amgen. ",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/ajh.25896",

language = "English (US)",

volume = "95",

pages = "E245--E247",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

AU - Samra, Bachar

AU - Alotaibi, Ahmad S.

AU - Short, Nicholas J.

AU - Khoury, Joseph D.

AU - Ravandi, Farhad

AU - Garris, Rebecca

AU - Jain, Nitin

AU - Konopleva, Marina

AU - Kantarjian, Hagop

AU - Jabbour, Elias

N1 - Funding Information: E. Jabbour: Research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. F. Ravandi: Honoraria/member advisory boards with BMS, Novartis, AbbVie and Amgen. M. Konopleva: Consulting/honoraria from AbbVie, Genentech, F. Hoffman La‐Roche, Stemline Therapeutics, Amgen, Forty‐Seven, Kisoji; research funding/clinical trials support: AbbVie, Genentech, F. Hoffman La‐Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca, Forty‐Seven; stock options/royalties: Reata Pharmaceutical. H. Kantarjian: Grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi‐Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. N.J. Short has served as consultant for Takeda Oncology and AstraZeneca, reports receiving commercial research grants from Takeda Oncology and Astellas Pharma Inc., and has received speakers’ bureau honoraria from Amgen.

PY - 2020/9/1

Y1 - 2020/9/1

UR - https://www.scopus.com/pages/publications/85088802464

UR - https://www.scopus.com/pages/publications/85088802464#tab=citedBy

U2 - 10.1002/ajh.25896

DO - 10.1002/ajh.25896

M3 - Letter

C2 - 32501545

AN - SCOPUS:85088802464

SN - 0361-8609

VL - 95

SP - E245-E247

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 9

ER -

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this